Funding will advance discovery of novel anti-infectives addressing antimicrobial resistance.

ArrePath, a drug discovery spinout founded by Zemer Gitai, the Edwin Grant Conklin Professor of Biology and professor of molecular biology, has announced a seed round of $20 million to advance its proprietary, machine learning-based platform for discovering new classes of anti-infectives. The startup is addressing the global need for new antibiotics that more effectively treat drug-resistant infections and overcome antimicrobial resistance. Read full story.